{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:07:37Z","timestamp":1791544057662,"version":"4.3.4"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009002","name":"Ministry of Education and Science","doi-asserted-by":"publisher","award":["SKN\/SN\/496937\/2021"],"award-info":[{"award-number":["SKN\/SN\/496937\/2021"]}],"id":[{"id":"10.13039\/100009002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Second-generation antipsychotics are widely used for the treatment of schizophrenia. Aripiprazole (ARI) is classified as a third-generation antipsychotic drug with a high affinity for dopamine and serotonin receptors. It is considered a dopamine-system stabilizer without severe side effects. In some patients the response to ARI treatment is inadequate and they require an effective augmentation strategy. It has been found that the response to the drug and the risk of adverse metabolic effects can be related to gene polymorphisms. A reduced dose is recommended for CYP2D6 poor metabolizers; moreover, it is postulated that other polymorphisms including\n                    <jats:italic>CYP3A4<\/jats:italic>\n                    ,\n                    <jats:italic>CYP3A5<\/jats:italic>\n                    ,\n                    <jats:italic>ABCB1<\/jats:italic>\n                    ,\n                    <jats:italic>DRD2,<\/jats:italic>\n                    and\n                    <jats:italic>5-HTRs<\/jats:italic>\n                    genes influence the therapeutic effect of ARI. ARI can increase the levels of prolactin, C-peptide, insulin, and\/or cholesterol possibly due to specific genetic variants. It seems that a pharmacogenetic approach can help predict drug response and improve the clinical management of patients with schizophrenia.\n                  <\/jats:p>","DOI":"10.1007\/s43440-022-00440-6","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T13:02:47Z","timestamp":1671195767000},"page":"19-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Antipsychotic drug\u2014aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms"],"prefix":"10.1007","volume":"75","author":[{"given":"Adriana","family":"Stelmach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Guzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Ro\u017cnowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Najbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9869-321X","authenticated-orcid":false,"given":"Anna","family":"Sadakierska-Chudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"issue":"5","key":"440_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2174\/138161210790361461","volume":"16","author":"RB Mailman","year":"2010","unstructured":"Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16(5):488\u2013501.","journal-title":"Curr Pharm Des"},{"issue":"8","key":"440_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2020.1795126","volume":"19","author":"L Orsolini","year":"2020","unstructured":"Orsolini L, De Berardis D, Volpe U. Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opin Drug Saf. 2020;19(8):981\u201398.","journal-title":"Expert Opin Drug Saf"},{"issue":"29","key":"440_CR3","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","volume":"16","author":"P Li","year":"2016","unstructured":"Li P, Snyder GL, Vanover KE. Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr Top Med Chem. 2016;16(29):3385\u2013403.","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"440_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","volume":"22","author":"S Smith","year":"2002","unstructured":"Smith S, Wheeler MJ, Murray R, O\u2019Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol. 2002;22(2):109\u201314.","journal-title":"J Clin Psychopharmacol"},{"key":"440_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/B978-0-08-097086-8.27064-5","volume-title":"International Encyclopedia of the Social and Behavioral Sciences","author":"T Pollm\u00e4cher","year":"2015","unstructured":"Pollm\u00e4cher T. Treatment of schizophrenia. In: Wright JA, editor. International Encyclopedia of the Social and Behavioral Sciences. 2nd ed. Elsevier; 2015. p. 16\u201320.","edition":"2"},{"issue":"1","key":"440_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12944-020-01203-z","volume":"19","author":"FT Endomba","year":"2020","unstructured":"Endomba FT, Tankeu AT, Nkeck JR, Tochie JN. Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain? Lipids Health Dis. 2020;19(1):22.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"440_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","volume":"7","author":"A U\u00e7ok","year":"2008","unstructured":"U\u00e7ok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008;7(1):58\u201362.","journal-title":"World Psychiatry"},{"issue":"10","key":"440_CR8","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.3390\/ijms19103105","volume":"19","author":"M Kondej","year":"2018","unstructured":"Kondej M, St\u0119pnicki P, Kaczor AA. Multi-target approach for drug discovery against schizophrenia. Int J Mol Sci. 2018;19(10):3105.","journal-title":"Int J Mol Sci"},{"key":"440_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.711940","volume":"12","author":"P Soria-Chacartegui","year":"2021","unstructured":"Soria-Chacartegui P, Villapalos-Garc\u00eda G, Zubiaur P, Abad-Santos F, Koller D. Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone. Front Pharmacol. 2021;12: 711940.","journal-title":"Front Pharmacol"},{"issue":"12","key":"440_CR10","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s40262-021-01041-x","volume":"60","author":"LA Kneller","year":"2021","unstructured":"Kneller LA, Zubiaur P, Koller D, Abad-Santos F, Hempel G. Influence of CYP2D6 phenotypes on the pharmacokinetics of aripiprazole and dehydro-aripiprazole using a physiologically based pharmacokinetic approach. Clin Pharmacokinet. 2021;60(12):1569\u201382.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"440_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bcpt.13384","volume":"126","author":"L Baandrup","year":"2020","unstructured":"Baandrup L. Polypharmacy in schizophrenia. Basic Clin Pharmacol Toxicol. 2020;126(3):183\u201392.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"440_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/bmb\/ldv017","volume":"114","author":"J Lally","year":"2015","unstructured":"Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015;114(1):169\u201379.","journal-title":"Br Med Bull"},{"issue":"1","key":"440_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41537-021-00158-z","volume":"7","author":"DD Kim","year":"2021","unstructured":"Kim DD, Barr AM, Lian L, Yuen JWY, Fredrikson D, Honer WG, et al. Efficacy and tolerability of aripiprazole versus D. NPJ Schizophr. 2021;7(1):29.","journal-title":"NPJ Schizophr"},{"issue":"7","key":"440_CR14","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1017\/S1461145709009948","volume":"12","author":"M Han","year":"2009","unstructured":"Han M, Huang XF, Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropsychopharmacol. 2009;12(7):941\u201352.","journal-title":"Int J Neuropsychopharmacol"},{"key":"440_CR15","unstructured":"Gettu N, Saadabadi A. Aripiprazole. [Updated 2022 May 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. PMID: 31613519. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547739\/"},{"issue":"1\u20132","key":"440_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mce.2011.09.020","volume":"357","author":"HJ Lee","year":"2012","unstructured":"Lee HJ, Ormandy CJ. Interplay between progesterone and prolactin in mammary development and implications for breast cancer. Mol Cell Endocrinol. 2012;357(1\u20132):101\u20137.","journal-title":"Mol Cell Endocrinol"},{"key":"440_CR17","doi-asserted-by":"publisher","first-page":"25998","DOI":"10.1038\/srep25998","volume":"6","author":"M Wang","year":"2016","unstructured":"Wang M, Wu X, Chai F, Zhang Y, Jiang J. Plasma prolactin and breast cancer risk: a meta- analysis. Sci Rep. 2016;6:25998.","journal-title":"Sci Rep"},{"issue":"10","key":"440_CR18","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","volume":"8","author":"H Taipale","year":"2021","unstructured":"Taipale H, Solmi M, L\u00e4hteenvuo M, Tanskanen A, Correll CU, Tiihonen J. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021;8(10):883\u201391.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"440_CR19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1742-1241.2003.tb11397.x","volume":"57","author":"DM Taylor","year":"2003","unstructured":"Taylor DM. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract. 2003;57(1):49\u201354.","journal-title":"Int J Clin Pract"},{"issue":"11","key":"440_CR20","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.3390\/ijms19113342","volume":"19","author":"JF Plows","year":"2018","unstructured":"Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci. 2018;19(11):3342.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"440_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40263-018-0517-5","volume":"32","author":"P Damkier","year":"2018","unstructured":"Damkier P, Videbech P. The safety of second-generation antipsychotics during pregnancy: a clinically focused review. CNS Drugs. 2018;32(4):351\u201366.","journal-title":"CNS Drugs"},{"key":"440_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jad.2018.06.004","volume":"238","author":"M Galbally","year":"2018","unstructured":"Galbally M, Frayne J, Watson SJ, Snellen M. Aripiprazole and pregnancy: a retrospective, multicentre study. J Affect Disord. 2018;238:593\u20136.","journal-title":"J Affect Disord"},{"key":"440_CR23","doi-asserted-by":"publisher","first-page":"204512532199127","DOI":"10.1177\/2045125321991277","volume":"11","author":"B Fern\u00e1ndez-Abascal","year":"2021","unstructured":"Fern\u00e1ndez-Abascal B, Recio-Barbero M, S\u00e1enz-Herrero M, Segarra R. Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. Ther Adv Psychopharmacol. 2021;11:2045125321991277.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"4","key":"440_CR24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.pnpbp.2006.02.001","volume":"30","author":"BH Lee","year":"2006","unstructured":"Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(4):714\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"440_CR25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1055\/s-2008-1076721","volume":"41","author":"AJ Sheldrick","year":"2008","unstructured":"Sheldrick AJ, Gr\u00fcnder G. Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis. Pharmacopsychiatry. 2008;41(4):160.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"440_CR26","first-page":"617","volume":"81","author":"J Muench","year":"2010","unstructured":"Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617\u201322.","journal-title":"Am Fam Physician"},{"key":"440_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1741-7015-3-15","volume":"3","author":"CE Adams","year":"2005","unstructured":"Adams CE, Rathbone J, Thornley B, Clarke M, Borrill J, Wahlbeck K, et al. Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Med. 2005;3:15.","journal-title":"BMC Med"},{"key":"440_CR28","first-page":"CD007778","volume":"2","author":"X Liu","year":"2009","unstructured":"Liu X, De Haan S. Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst Rev. 2009;2:CD007778.","journal-title":"Cochrane Database Syst Rev"},{"key":"440_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","volume":"13","author":"M Solmi","year":"2017","unstructured":"Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757\u201377.","journal-title":"Ther Clin Risk Manag"},{"issue":"41","key":"440_CR30","first-page":"687","volume":"108","author":"K Wenzel-Seifert","year":"2011","unstructured":"Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108(41):687\u201393.","journal-title":"Dtsch Arztebl Int"},{"issue":"20","key":"440_CR31","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.2174\/1381612043383872","volume":"10","author":"P Pacher","year":"2004","unstructured":"Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004;10(20):2463\u201375.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"440_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2125.2004.02098.x","volume":"58","author":"S Hennessy","year":"2004","unstructured":"Hennessy S, Bilker WB, Knauss JS, Kimmel SE, Margolis DJ, Morrison MF, et al. Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol. Br J Clin Pharmacol. 2004;58(1):81\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"440_CR33","unstructured":"Feinberg SM, Fariba KA, Saadabadi A. Thioridazine. [Updated 2022 May 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459140\/"},{"issue":"6","key":"440_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2165\/00003088-199937060-00001","volume":"37","author":"S Kudo","year":"1999","unstructured":"Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37(6):435\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"26","key":"440_CR35","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1808217","volume":"379","author":"TD Girard","year":"2018","unstructured":"Girard TD, Exline MC, Carson SS, Hough CL, Rock P, Gong MN, et al. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2018;379(26):2506\u201316.","journal-title":"N Engl J Med"},{"key":"440_CR36","unstructured":"Rahman S, Marwaha R. Haloperidol. 2022 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan\u2013. PMID: 32809727."},{"issue":"10202","key":"440_CR37","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351.","journal-title":"Lancet"},{"issue":"1","key":"440_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-197612010-00001","volume":"12","author":"RM Pinder","year":"1976","unstructured":"Pinder RM, Brogden RN, Swayer R, Speight TM, Spencer R, Avery GS. Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. Drugs. 1976;12(1):1\u201340.","journal-title":"Drugs"},{"issue":"3","key":"440_CR39","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/00007611-199303000-00019","volume":"86","author":"MJ Tueth","year":"1993","unstructured":"Tueth MJ, Cheong JA. Clinical uses of pimozide. South Med J. 1993;86(3):344\u20139.","journal-title":"South Med J"},{"key":"440_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/B978-0-12-805157-3.00007-7","volume-title":"Piperidine-Based Drug Discovery","author":"R Vardanyan","year":"2017","unstructured":"Vardanyan R. Piperidine-Based Nonfused Biheterocycles With C-N and C\u2013C Coupling. In: Vardanyan R, editor. Piperidine-Based Drug Discovery. Elsevier; 2017. p. 241\u201367."},{"issue":"13","key":"440_CR41","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1503\/cmaj.1041064","volume":"172","author":"DM Gardner","year":"2005","unstructured":"Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172(13):1703\u201311.","journal-title":"CMAJ"},{"key":"440_CR42","unstructured":"Siragusa S, Bistas KG, Saadabadi A. Fluphenazine. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. PMID: 29083807.Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459194\/"},{"key":"440_CR43","first-page":"395","volume-title":"Meyler's side effects of drugs. The International Encyclopedia of adverse drug reactions and interactions","author":"JK Aronson","year":"2015","unstructured":"Aronson JK. Fluphenazine. In: Aronson JK, editor. Meyler\u2019s side effects of drugs. The International Encyclopedia of adverse drug reactions and interactions. 16th ed. Elsevier Science; 2015. p. 395\u2013401.","edition":"16"},{"issue":"3","key":"440_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2125.2010.03783.x","volume":"71","author":"SK Praharaj","year":"2011","unstructured":"Praharaj SK, Jana AK, Goyal N, Sinha VK. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71(3):377\u201382.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"440_CR45","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/ph14030238","volume":"14","author":"M Carli","year":"2021","unstructured":"Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, Aringhieri S, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021;14(3):238.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"440_CR46","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323.","journal-title":"N Engl J Med"},{"key":"440_CR47","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2147\/NDT.S113099","volume":"13","author":"M Dayabandara","year":"2017","unstructured":"Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231\u201341.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"440_CR48","unstructured":"Thomas K, Saadabadi A. Olanzapine. [Updated 2022 Sep 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. PMID: 30422498. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK532903\/"},{"issue":"1","key":"440_CR49","first-page":"54","volume":"28","author":"P Jaho\u0142kowski","year":"2019","unstructured":"Jaho\u0142kowski P, Mierzejewski P, \u015awitaj P. Clozapine-induced myocarditis. Adv Psychiatry Neurol\/Post\u0119py Psychiatrii i Neurologii. 2019;28(1):54\u201369.","journal-title":"Adv Psychiatry Neurol\/Post\u0119py Psychiatrii i Neurologii"},{"issue":"Suppl 2","key":"440_CR50","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/j.euroneuro.2008.02.004","volume":"18","author":"AL Montejo","year":"2008","unstructured":"Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008;18(Suppl 2):S108-114.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"440_CR51","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2165\/00003495-199040050-00007","volume":"40","author":"A Fitton","year":"1990","unstructured":"Fitton A, Heel RC. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs. 1990;40(5):722\u201347.","journal-title":"Drugs"},{"issue":"Suppl 8","key":"440_CR52","first-page":"14","volume":"61","author":"DD Miller","year":"2000","unstructured":"Miller DD. Review and management of clozapine side effects. J Clin Psychiatry. 2000;61(Suppl 8):14\u20137 (discussion 18\u201319).","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"440_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JCP.0000000000001329","volume":"41","author":"G Blackman","year":"2021","unstructured":"Blackman G, Lisshammar JEL, Zafar R, Pollak TA, Pritchard M, Cullen AE, et al. Clozapine response in schizophrenia and hematological changes. J Clin Psychopharmacol. 2021;41(1):19\u201324.","journal-title":"J Clin Psychopharmacol"},{"key":"440_CR54","unstructured":"Haidary HA, Padhy RK. Clozapine. [Updated 2021 Dec 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. PMID: 30571020. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535399\/"},{"issue":"2\u20133","key":"440_CR55","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","volume":"123","author":"C Rummel-Kluge","year":"2010","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2\u20133):225\u201333.","journal-title":"Schizophr Res"},{"key":"440_CR56","unstructured":"McNeil SE, Gibbons JR, Cogburn M. Risperidone. [Updated 2022 May 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. PMID: 29083663. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459313\/"},{"issue":"7","key":"440_CR57","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00003088-200140070-00003","volume":"40","author":"CL DeVane","year":"2001","unstructured":"DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509\u201322.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"440_CR58","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2165\/11203840-000000000-00000","volume":"26","author":"M Sanford","year":"2012","unstructured":"Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs. 2012;26(5):435\u201360.","journal-title":"CNS Drugs"},{"issue":"1","key":"440_CR59","first-page":"51","volume":"42","author":"RR Conley","year":"2005","unstructured":"Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci. 2005;42(1):51\u201360.","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"440_CR60","unstructured":"Maan JS, Ershadi M, Khan I, et al. Quetiapine. [Updated 2022 Sep 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. PMID: 29083706. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459145\/"},{"issue":"2","key":"440_CR61","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1527-3458.2007.00008.x","volume":"13","author":"WM Greenberg","year":"2007","unstructured":"Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13(2):137\u201377.","journal-title":"CNS Drug Rev"},{"issue":"12","key":"440_CR62","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2165\/00023210-200620120-00006","volume":"20","author":"T Swainston Harrison","year":"2006","unstructured":"Swainston Harrison T, Scott LJ. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. CNS Drugs. 2006;20(12):1027\u201352.","journal-title":"CNS Drugs"},{"key":"440_CR63","unstructured":"Bouchette D, Fariba KA, Marwaha R. Ziprasidone. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. PMID: 28846230. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448157\/"},{"issue":"7","key":"440_CR64","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60(7):681\u201390.","journal-title":"Arch Gen Psychiatry"},{"key":"440_CR65","volume-title":"Medical genetics summaries","author":"L Dean","year":"2012","unstructured":"Dean L, Kane M. Clozapine therapy and CYP genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ, editors. Medical genetics summaries. Bethesda, MD, USA: National Center for Biotechnology Information (US); 2012."},{"issue":"6","key":"440_CR66","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/bcpt.12960","volume":"122","author":"C Belmonte","year":"2018","unstructured":"Belmonte C, Ochoa D, Rom\u00e1n M, Saiz-Rodr\u00edguez M, Wojnicz A, G\u00f3mez-S\u00e1nchez CI, et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin Pharmacol Toxicol. 2018;122(6):596\u2013605.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"9","key":"440_CR67","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","volume":"29","author":"F Corponi","year":"2019","unstructured":"Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, et al. Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29(9):971\u201385.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"440_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852915000954","volume":"21","author":"SM Stahl","year":"2016","unstructured":"Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 2016;21(1):1\u20136.","journal-title":"CNS Spectr"},{"issue":"9","key":"440_CR69","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1176\/appi.ajp.2015.15060741","volume":"172","author":"DC Goff","year":"2015","unstructured":"Goff DC. Brexpiprazole: a new antipsychotic following in the footsteps of aripiprazole. Am J Psychiatry. 2015;172(9):820\u20131.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"440_CR70","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1017\/S1092852916000043","volume":"21","author":"SM Stahl","year":"2016","unstructured":"Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016;21(2):123\u20137.","journal-title":"CNS Spectr"},{"issue":"2","key":"440_CR71","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/npr2.12180","volume":"41","author":"T Kikuchi","year":"2021","unstructured":"Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD. Discovery research and development history of the dopamine D. Neuropsychopharmacol Rep. 2021;41(2):134\u201343.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"9","key":"440_CR72","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","volume":"164","author":"D Mamo","year":"2007","unstructured":"Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007;164(9):1411\u20137.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"440_CR73","doi-asserted-by":"publisher","first-page":"923","DOI":"10.4088\/JCP.v62n1201","volume":"62","author":"SM Stahl","year":"2001","unstructured":"Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry. 2001;62(12):923\u20134.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"440_CR74","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4088\/JCP.v62n1101","volume":"62","author":"SM Stahl","year":"2001","unstructured":"Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, \u201cGoldilocks\u201d actions at dopamine receptors. J Clin Psychiatry. 2001;62(11):841\u20132.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"440_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046488","volume":"7","author":"H Ito","year":"2012","unstructured":"Ito H, Takano H, Arakawa R, Takahashi H, Kodaka F, Takahata K, et al. Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[\u03b2-11C]DOPA. PLoS ONE. 2012;7(9): e46488.","journal-title":"PLoS ONE"},{"issue":"8","key":"440_CR76","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","volume":"15","author":"EW Tuplin","year":"2017","unstructured":"Tuplin EW, Holahan MR. Aripiprazole, a drug that displays partial agonism and functional selectivity. Curr Neuropharmacol. 2017;15(8):1192\u2013207.","journal-title":"Curr Neuropharmacol"},{"key":"440_CR77","first-page":"47","volume":"5","author":"R Brisch","year":"2014","unstructured":"Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014;5:47.","journal-title":"Front Psychiatry"},{"issue":"1","key":"440_CR78","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/sj.npp.1301071","volume":"32","author":"JD Urban","year":"2007","unstructured":"Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology. 2007;32(1):67\u201377.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"440_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132722","volume":"10","author":"B Pan","year":"2015","unstructured":"Pan B, Chen J, Lian J, Huang XF, Deng C. Unique effects of acute aripiprazole treatment on the dopamine D2 receptor downstream cAMP-PKA and Akt-GSK3\u03b2 signalling pathways in rats. PLoS ONE. 2015;10(7): e0132722.","journal-title":"PLoS ONE"},{"issue":"1","key":"440_CR80","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12031-016-0730-y","volume":"59","author":"B Pan","year":"2016","unstructured":"Pan B, Lian J, Huang XF, Deng C. Aripiprazole increases the PKA signalling and expression of the GABAA receptor and CREB1 in the nucleus accumbens of rats. J Mol Neurosci. 2016;59(1):36\u201347.","journal-title":"J Mol Neurosci"},{"key":"440_CR81","doi-asserted-by":"publisher","first-page":"30040","DOI":"10.1038\/srep30040","volume":"6","author":"B Pan","year":"2016","unstructured":"Pan B, Huang XF, Deng C. Chronic administration of aripiprazole activates GSK3\u03b2-dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats. Sci Rep. 2016;6:30040.","journal-title":"Sci Rep"},{"issue":"11","key":"440_CR82","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1177\/0269881118788822","volume":"32","author":"B Pan","year":"2018","unstructured":"Pan B, Lian J, Deng C. Chronic antipsychotic treatment differentially modulates protein kinase A- and glycogen synthase kinase 3 beta-dependent signaling pathways, N-methyl-D-aspartate receptor and \u03b3-aminobutyric acid A receptors in nucleus accumbens of juvenile rats. J Psychopharmacol. 2018;32(11):1252\u201363.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"440_CR83","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4306\/pi.2013.10.1.75","volume":"10","author":"JS Lee","year":"2013","unstructured":"Lee JS, Lee JD, Park HJ, Oh MK, Chun JW, Kim SJ, et al. Is the GABA system related to the social competence improvement effect of aripiprazole? An (18)F-Fluoroflumazenil PET study. Psychiatry Investig. 2013;10(1):75\u201380.","journal-title":"Psychiatry Investig"},{"key":"440_CR84","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.psychres.2019.02.001","volume":"273","author":"J Lian","year":"2019","unstructured":"Lian J, Deng C. Early antipsychotic exposure affects NMDA and GABAA receptor binding in the brains of juvenile rats. Psychiatry Res. 2019;273:739\u201345.","journal-title":"Psychiatry Res"},{"issue":"11","key":"440_CR85","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2165\/00023210-200216110-00008","volume":"16","author":"JK McGavin","year":"2002","unstructured":"McGavin JK, Goa KL. Aripiprazole. CNS Drugs. 2002;16(11):779\u201386. https:\/\/doi.org\/10.2165\/00023210-200216110-00008.","journal-title":"CNS Drugs"},{"issue":"1","key":"440_CR86","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103\u201341.","journal-title":"Pharmacol Ther"},{"issue":"23","key":"440_CR87","doi-asserted-by":"publisher","first-page":"12808","DOI":"10.3390\/ijms222312808","volume":"22","author":"M Zhao","year":"2021","unstructured":"Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021;22(23):12808.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"440_CR88","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/npp.2015.5","volume":"40","author":"G Blasi","year":"2015","unstructured":"Blasi G, Selvaggi P, Fazio L, Antonucci LA, Taurisano P, Masellis R, et al. Variation in dopamine D2 and serotonin 5-HT2A receptor genes is associated with working memory processing and response to treatment with antipsychotics. Neuropsychopharmacology. 2015;40(7):1600\u20138.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"440_CR89","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/genes11111295","volume":"11","author":"C Taylor","year":"2020","unstructured":"Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A review of the important role of CYP2D6 in pharmacogenomics. Genes. 2020;11(11):1295.","journal-title":"Genes"},{"key":"440_CR90","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fphar.2018.00305","volume":"9","author":"AL Del Tredici","year":"2018","unstructured":"Del Tredici AL, Malhotra A, Dedek M, Espin F, Roach D, Zhu GD, et al. Frequency of CYP2D6 alleles including structural variants in the United States. Front Pharmacol. 2018;9:305.","journal-title":"Front Pharmacol"},{"key":"440_CR91","unstructured":"Kane M. CYP2D6 Overview: Allele and Phenotype Frequencies. 2021 Oct 15. In: Pratt VM, Scott SA, Pirmohamed M, et al., (eds). Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574601\/"},{"issue":"7","key":"440_CR92","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/FPC.0b013e32832e0e97","volume":"19","author":"RP Owen","year":"2009","unstructured":"Owen RP, Sangkuhl K, Klein TE, Altman RB. Cytochrome P450 2D6. Pharmacogenet Genomics. 2009;19(7):559\u201362.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"440_CR93","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1517\/17425255.2011.532787","volume":"7","author":"JP Zhang","year":"2011","unstructured":"Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol. 2011;7(1):9\u201337.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"440_CR94","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1517\/14622416.3.2.229","volume":"3","author":"LD Bradford","year":"2002","unstructured":"Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):229\u201343.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"440_CR95","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gim.2016.80","volume":"19","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19(1):69\u201376.","journal-title":"Genet Med"},{"issue":"1","key":"440_CR96","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41431-019-0480-8","volume":"28","author":"J Petrovi\u0107","year":"2020","unstructured":"Petrovi\u0107 J, Pe\u0161i\u0107 V, Lauschke VM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet. 2020;28(1):88\u201394.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"440_CR97","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00228-019-02768-0","volume":"76","author":"M Tveito","year":"2020","unstructured":"Tveito M, Molden E, H\u00f8iseth G, Correll CU, Smith RL. Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status. Eur J Clin Pharmacol. 2020;76(1):41\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"440_CR98","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/jcpt.12780","volume":"44","author":"X Zhang","year":"2019","unstructured":"Zhang X, Xiang Q, Zhao X, Ma L, Cui Y. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: a systematic review and meta-analysis. J Clin Pharm Ther. 2019;44(2):163\u201373.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"440_CR99","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2217\/pgs-2020-0134","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liu C, Zhou S, Xie R, He X, Wang Z, et al. Influence of YP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects. Pharmacogenomics. 2021;22(4):213\u201323.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"440_CR100","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JCP.0000000000000070","volume":"34","author":"K van der Weide","year":"2014","unstructured":"van der Weide K, van der Weide J. The influence of the CYP3A4*22 polymorphism on serum concentration of quetiapine in psychiatric patients. J Clin Psychopharmacol. 2014;34(2):256\u201360.","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"440_CR101","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1111\/bcp.14300","volume":"86","author":"D Koller","year":"2020","unstructured":"Koller D, Saiz-Rodr\u00edguez M, Zubiaur P, Ochoa D, Almenara S, Rom\u00e1n M, et al. The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial. Br J Clin Pharmacol. 2020;86(10):2051\u201362.","journal-title":"Br J Clin Pharmacol"},{"issue":"17","key":"440_CR102","first-page":"4955","volume":"62","author":"T Illmer","year":"2002","unstructured":"Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62(17):4955\u201362.","journal-title":"Cancer Res"},{"issue":"6","key":"440_CR103","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.bcp.2009.10.026","volume":"79","author":"SJ Hemauer","year":"2010","unstructured":"Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ, Patrikeeva SL, Hankins GD, Ahmed MS. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol. 2010;79(6):921\u20135.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"440_CR104","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/sj.mp.4000532","volume":"4","author":"EG J\u00f6nsson","year":"1999","unstructured":"J\u00f6nsson EG, N\u00f6then MM, Gr\u00fcnhage F, Farde L, Nakashima Y, Propping P, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry. 1999;4(3):290\u20136.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"440_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neulet.2004.11.014","volume":"376","author":"S Wu","year":"2005","unstructured":"Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett. 2005;376(1):1\u20134.","journal-title":"Neurosci Lett"},{"issue":"4","key":"440_CR106","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1017\/S1461145704004389","volume":"7","author":"HY Lane","year":"2004","unstructured":"Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol. 2004;7(4):461\u201370.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"440_CR107","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/hmg\/ddg055","volume":"12","author":"J Duan","year":"2003","unstructured":"Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet. 2003;12(3):205\u201316.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"440_CR108","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jpsychires.2008.09.005","volume":"43","author":"YC Shen","year":"2009","unstructured":"Shen YC, Chen SF, Chen CH, Lin CC, Chen SJ, Chen YJ, et al. Effects of DRD2\/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res. 2009;43(6):600\u20136.","journal-title":"J Psychiatr Res"},{"key":"440_CR109","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12993-016-0114-z","volume":"1","author":"TB Gonz\u00e1lez-Castro","year":"2016","unstructured":"Gonz\u00e1lez-Castro TB, Hern\u00e1ndez-D\u00edaz Y, Ju\u00e1rez-Rojop IE, L\u00f3pez-Narv\u00e1ez ML, Tovilla-Z\u00e1rate CA, Genis-Mendoza A, et al. The role of C957T, TaqI and Ser311Cys polymorphisms of the DRD2 gene in schizophrenia: systematic review and meta-analysis. Behav Brain Funct. 2016;1:29.","journal-title":"Behav Brain Funct"},{"issue":"12","key":"440_CR110","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.euroneuro.2008.07.010","volume":"18","author":"JS Kwon","year":"2008","unstructured":"Kwon JS, Kim E, Kang DH, Choi JS, Yu KS, Jang IJ, et al. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol. 2008;18(12):897\u2013907.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"440_CR111","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/jnr.10173","volume":"67","author":"OO Polesskaya","year":"2002","unstructured":"Polesskaya OO, Sokolov BP. Differential expression of the \u201cC\u201d and \u201cT\u201d alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res. 2002;67(6):812\u201322.","journal-title":"J Neurosci Res"},{"issue":"9","key":"440_CR112","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1176\/ajp.156.9.1456","volume":"156","author":"G Turecki","year":"1999","unstructured":"Turecki G, Bri\u00e8re R, Dewar K, Antonetti T, Lesage AD, S\u00e9guin M, et al. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry. 1999;156(9):1456\u20138.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"440_CR113","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1176\/appi.ajp.159.9.1593","volume":"159","author":"HY Lane","year":"2002","unstructured":"Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry. 2002;159(9):1593\u20135.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"440_CR114","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000327602","volume":"64","author":"L Olajossy-Hilkesberger","year":"2011","unstructured":"Olajossy-Hilkesberger L, Godlewska B, Schosser-Haupt A, Olajossy M, Wojcierowski J, Landowski J, et al. Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia. Neuropsychobiology. 2011;64(4):202\u201310.","journal-title":"Neuropsychobiology"},{"issue":"2","key":"440_CR115","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00213-009-1538-z","volume":"205","author":"SF Chen","year":"2009","unstructured":"Chen SF, Shen YC, Chen CH. HTR2A A-1438G\/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology. 2009;205(2):285\u201392.","journal-title":"Psychopharmacology"},{"issue":"5","key":"440_CR116","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s12325-010-0035-4","volume":"27","author":"T Sumiyoshi","year":"2010","unstructured":"Sumiyoshi T, Tsunoda M, Higuchi Y, Itoh T, Seo T, Itoh H, et al. Serotonin-1A receptor gene polymorphism and the ability of antipsychotic drugs to improve attention in schizophrenia. Adv Ther. 2010;27(5):307\u201313.","journal-title":"Adv Ther"},{"issue":"10","key":"440_CR117","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1176\/ajp.2006.163.10.1826","volume":"163","author":"GP Reynolds","year":"2006","unstructured":"Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry. 2006;163(10):1826\u20139.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"440_CR118","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/0269881107081522","volume":"22","author":"L Wang","year":"2008","unstructured":"Wang L, Fang C, Zhang A, Du J, Yu L, Ma J, et al. The \u20131019 C\/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol. 2008;22(8):904\u20139.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"440_CR119","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4088\/JCP.v68n0206","volume":"68","author":"JM Kane","year":"2007","unstructured":"Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;68(2):213\u201323.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"440_CR120","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s12325-020-01566-w","volume":"38","author":"D Koller","year":"2021","unstructured":"Koller D, Almenara S, Mej\u00eda G, Saiz-Rodr\u00edguez M, Zubiaur P, Rom\u00e1n M, et al. Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a randomised crossover clinical trial in healthy volunteers: association with pharmacogenetics. Adv Ther. 2021;38(2):1035\u201354.","journal-title":"Adv Ther"},{"issue":"8","key":"440_CR121","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400\u201311.","journal-title":"Neuropsychopharmacology"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-022-00440-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-022-00440-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-022-00440-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T23:55:07Z","timestamp":1701561307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-022-00440-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1007\/s43440-022-00440-6","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}